Tumour Dormancy and Clinical Implications in Breast Cancer

Overview

Journal Ecancermedicalscience

Specialty Oncology

Date 2013 May 30

PMID 23717341

Citations 17

Authors

L Gelao

C Criscitiello

L Fumagalli

M Locatelli

S Manunta

A Esposito

I Minchella

A Goldhirsch

G Curigliano

Affiliations

Soon will be listed here.

Abstract

The aim of adjuvant therapy in breast cancer is to reduce the risk of recurrence. Some patients develop metastases many years after apparently successful treatment of their primary cancer. Tumour dormancy may explain the long time between initial diagnosis and treatment of cancer, and occurrence of relapse. The regulation of the switch from clinical dormancy to cancer regrowth in locoregional and distant sites is poorly understood. In this review, we report some data supporting the existence of various factors that may explain cancer dormancy including genetic and epigenetic changes, angiogenic switch, microenvironment, and immunosurveillance. A better definition and understanding of these factors should allow the identification of patients at high risk of relapse and to develop new therapeutic strategies in order to improve prognosis.

Citing Articles

Applying artificial intelligence technology to assist with breast cancer diagnosis and prognosis prediction.

Jones M, Islam W, Faiz R, Chen X, Zheng B Front Oncol. 2022; 12:980793.

PMID: 36119479 PMC: 9471147. DOI: 10.3389/fonc.2022.980793.

Role of Neural (N)-Cadherin in Breast Cancer Cell Stemness and Dormancy in the Bone Microenvironment.

Maurizi A, Ciocca M, Giuliani C, Di Carlo I, Teti A Cancers (Basel). 2022; 14(5).

PMID: 35267624 PMC: 8909418. DOI: 10.3390/cancers14051317.

Specific N-cadherin-dependent pathways drive human breast cancer dormancy in bone marrow.

Sinha G, Ferrer A, Ayer S, El-Far M, Pamarthi S, Naaldijk Y Life Sci Alliance. 2021; 4(7).

PMID: 34078741 PMC: 8200294. DOI: 10.26508/lsa.202000969.

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.

Borrero-Garcia L, Maldonado M, Medina-Velazquez J, Troche-Torres A, Velazquez L, Grafals-Ruiz N BMC Cancer. 2021; 21(1):652.

PMID: 34074257 PMC: 8170972. DOI: 10.1186/s12885-021-08366-7.

A Case of Pulmonary Metastasis of Breast Cancer 23 Years after Surgery Accompanied with Non-Tuberculous Mycobacterium Infection.

Yabuuchi Y, Nakagawa T, Shimanouchi M, Usui S, Hayashihara K, Oh-Ishi S Case Rep Oncol. 2021; 13(3):1357-1363.

PMID: 33442355 PMC: 7772832. DOI: 10.1159/000511072.

References

Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S . Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009; 27(13):2177-84. DOI: 10.1200/JCO.2008.18.0497. View

Folkman J, Watson K, Ingber D, Hanahan D . Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989; 339(6219):58-61. DOI: 10.1038/339058a0. View

Aguirre-Ghiso J, Liu D, Mignatti A, Kovalski K, OSSOWSKI L . Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001; 12(4):863-79. PMC: 32272. DOI: 10.1091/mbc.12.4.863. View

Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent D . Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol. 2011; 29(31):4199-204. DOI: 10.1200/JCO.2011.35.5867. View

Racila E, Scheuermann R, Picker L, Yefenof E, Tucker T, Chang W . Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med. 1995; 181(4):1539-50. PMC: 2191969. DOI: 10.1084/jem.181.4.1539. View

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

Dunn G, Old L, Schreiber R . The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22:329-60. DOI: 10.1146/annurev.immunol.22.012703.104803. View

Teng M, Swann J, Koebel C, Schreiber R, Smyth M . Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol. 2008; 84(4):988-93. DOI: 10.1189/jlb.1107774. View

Carmeliet P, Dor Y, Herbert J, Fukumura D, Brusselmans K, Dewerchin M . Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998; 394(6692):485-90. DOI: 10.1038/28867. View

10.

Allgayer H, Aguirre-Ghiso J . The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?. APMIS. 2008; 116(7-8):602-14. PMC: 2821075. DOI: 10.1111/j.1600-0463.2008.00997.x. View

11.

White D, Kurpios N, Zuo D, Hassell J, Blaess S, Mueller U . Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell. 2004; 6(2):159-70. DOI: 10.1016/j.ccr.2004.06.025. View

12.

Janni W, Vogl F, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J . Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res. 2011; 17(9):2967-76. DOI: 10.1158/1078-0432.CCR-10-2515. View

13.

Lou H, Dean M . Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene. 2007; 26(9):1357-60. DOI: 10.1038/sj.onc.1210200. View

14.

Tlsty T, Coussens L . Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2007; 1:119-50. DOI: 10.1146/annurev.pathol.1.110304.100224. View

15.

Cervi D, Yip T, Bhattacharya N, Podust V, Peterson J, Abou-Slaybi A . Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2007; 111(3):1201-7. DOI: 10.1182/blood-2007-04-084798. View

16.

Goss P, Chambers A . Does tumour dormancy offer a therapeutic target?. Nat Rev Cancer. 2010; 10(12):871-7. DOI: 10.1038/nrc2933. View

17.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

18.

Houghton A, Grisolano J, Baumann M, Kobayashi D, Hautamaki R, Nehring L . Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006; 66(12):6149-55. DOI: 10.1158/0008-5472.CAN-04-0297. View

19.

Bragado P, Sosa M, Keely P, Condeelis J, Aguirre-Ghiso J . Microenvironments dictating tumor cell dormancy. Recent Results Cancer Res. 2012; 195:25-39. PMC: 3516301. DOI: 10.1007/978-3-642-28160-0_3. View

20.

Pantel K, Alix-Panabieres C, Riethdorf S . Cancer micrometastases. Nat Rev Clin Oncol. 2009; 6(6):339-51. DOI: 10.1038/nrclinonc.2009.44. View